Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis.

Cancer medicine - 1 Dec 2024

Ke Zi-Hao, Chen Ying, Yu Tao, Zhang Qi, Xiang Yan, Lu Kai-Hua

Abstract excerpt

BACKGROUND: Immune biomarkers for non-small-cell lung cancer (NSCLC) are programmed death ligand 1 (PD-L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative. METHODS: We identified lipoprotein receptor-related protein 1B (LRP1B) mutation as a potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis

Share to Gene Expression Regulation, Neoplastic

Share to Immunotherapy

Share to Lymphocytes, Tumor-Infiltrating

Share to Receptors, LDL

Source

Open in PubMed Open full text

Identifiers

PMID: 39660409
DOI: 10.1002/cam4.70486
PMCID: PMC11632276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis.PMID 39660409Read ↗

LRP1B affects lung adenocarcinoma immunotherapy efficacy via ferroptosisSemantic proximity Read ↗

SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinomaSemantic proximity Read ↗

Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.Semantic proximity Read ↗

Regulation of Ferroptosis in Lung AdenocarcinomaSemantic proximity Read ↗

Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung CancerSemantic proximity Read ↗

Identification and Validation of a Ferroptosis-Related Gene to Predict Survival Outcomes and the Immune Microenvironment in Lung AdenocarcinomaSemantic proximity Read ↗

Ferroptosis and noncoding RNAs: exploring mechanisms in lung cancer treatmentSemantic proximity Read ↗

Identification of a Ferroptosis-related lncRNA Signature for Prognosis Prediction in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Ferroptosis-related gene AKR1C1 predicts the prognosis of non-small cell lung cancerSemantic proximity Read ↗

Molecular Identification of Immunity- and Ferroptosis-related Gene Signature in Non-small Cell Lung CancerSemantic proximity Read ↗

Emerging mechanisms of ferroptosis and its implications in lung cancerSemantic proximity Read ↗

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.